Financhill
Buy
58

INCY Quote, Financials, Valuation and Earnings

Last price:
$72.13
Seasonality move :
-3.94%
Day range:
$71.50 - $72.97
52-week range:
$50.35 - $83.95
Dividend yield:
0%
P/E ratio:
267.15x
P/S ratio:
3.61x
P/B ratio:
4.05x
Volume:
1.3M
Avg. volume:
1.6M
1-year change:
19.56%
Market cap:
$14B
Revenue:
$4.2B
EPS (TTM):
$0.27

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
INCY
Incyte
$1.1B $1.55 14.09% 40.38% $78.26
BMRN
Biomarin Pharmaceutical
$711M $0.74 14.07% 115.22% $96.71
BPMC
Blueprint Medicines
$145.2M -$0.71 66.77% -60.76% $126.79
EXEL
Exelixis
$563.2M $0.49 16.5% 248.48% $36.89
HALO
Halozyme Therapeutics
$285.7M $1.16 17.06% 57.62% $66.11
SNDX
Syndax Pharmaceuticals
$86.3M -$0.26 -- -74.42% $36.23
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
INCY
Incyte
$72.13 $78.26 $14B 267.15x $0.00 0% 3.61x
BMRN
Biomarin Pharmaceutical
$68.28 $96.71 $13B 31.04x $0.00 0% 4.75x
BPMC
Blueprint Medicines
$92.25 $126.79 $5.9B -- $0.00 0% 11.50x
EXEL
Exelixis
$36.85 $36.89 $10.3B 20.82x $0.00 0% 5.03x
HALO
Halozyme Therapeutics
$57.72 $66.11 $7.1B 16.83x $0.00 0% 7.35x
SNDX
Syndax Pharmaceuticals
$16.38 $36.23 $1.4B -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
INCY
Incyte
-- 0.833 -- 1.83x
BMRN
Biomarin Pharmaceutical
9.52% 0.496 4.75% 2.96x
BPMC
Blueprint Medicines
56.44% 2.337 6.96% 2.66x
EXEL
Exelixis
-- -0.022 -- 3.41x
HALO
Halozyme Therapeutics
80.54% 2.008 25.58% 6.50x
SNDX
Syndax Pharmaceuticals
-- 1.421 -- 6.92x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
INCY
Incyte
$1.1B $297.4M 0.81% 0.81% 26.65% $363.8M
BMRN
Biomarin Pharmaceutical
$611.2M $161.4M 6.92% 8.09% 23.05% $165.3M
BPMC
Blueprint Medicines
$138.9M -$41.2M -11.14% -24.43% -21.26% -$30.3M
EXEL
Exelixis
$546.8M $163.5M 23.63% 23.63% 28.84% $226.3M
HALO
Halozyme Therapeutics
$256M $175.5M 25.01% 162.37% 61.33% $175.4M
SNDX
Syndax Pharmaceuticals
-- -$89.6M -67.33% -67.33% -672.82% -$62.3M

Incyte vs. Competitors

  • Which has Higher Returns INCY or BMRN?

    Biomarin Pharmaceutical has a net margin of 17.07% compared to Incyte's net margin of 16.72%. Incyte's return on equity of 0.81% beat Biomarin Pharmaceutical's return on equity of 8.09%.

    Company Gross Margin Earnings Per Share Invested Capital
    INCY
    Incyte
    92.49% $1.02 $3.4B
    BMRN
    Biomarin Pharmaceutical
    81.78% $0.64 $6.3B
  • What do Analysts Say About INCY or BMRN?

    Incyte has a consensus price target of $78.26, signalling upside risk potential of 8.49%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $96.71 which suggests that it could grow by 41.64%. Given that Biomarin Pharmaceutical has higher upside potential than Incyte, analysts believe Biomarin Pharmaceutical is more attractive than Incyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    INCY
    Incyte
    10 15 0
    BMRN
    Biomarin Pharmaceutical
    15 7 0
  • Is INCY or BMRN More Risky?

    Incyte has a beta of 0.699, which suggesting that the stock is 30.125% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.285, suggesting its less volatile than the S&P 500 by 71.55%.

  • Which is a Better Dividend Stock INCY or BMRN?

    Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Incyte pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios INCY or BMRN?

    Incyte quarterly revenues are $1.2B, which are larger than Biomarin Pharmaceutical quarterly revenues of $747.3M. Incyte's net income of $201.2M is higher than Biomarin Pharmaceutical's net income of $124.9M. Notably, Incyte's price-to-earnings ratio is 267.15x while Biomarin Pharmaceutical's PE ratio is 31.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 3.61x versus 4.75x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INCY
    Incyte
    3.61x 267.15x $1.2B $201.2M
    BMRN
    Biomarin Pharmaceutical
    4.75x 31.04x $747.3M $124.9M
  • Which has Higher Returns INCY or BPMC?

    Blueprint Medicines has a net margin of 17.07% compared to Incyte's net margin of -34.13%. Incyte's return on equity of 0.81% beat Blueprint Medicines's return on equity of -24.43%.

    Company Gross Margin Earnings Per Share Invested Capital
    INCY
    Incyte
    92.49% $1.02 $3.4B
    BPMC
    Blueprint Medicines
    94.91% -$0.79 $685.6M
  • What do Analysts Say About INCY or BPMC?

    Incyte has a consensus price target of $78.26, signalling upside risk potential of 8.49%. On the other hand Blueprint Medicines has an analysts' consensus of $126.79 which suggests that it could grow by 37.44%. Given that Blueprint Medicines has higher upside potential than Incyte, analysts believe Blueprint Medicines is more attractive than Incyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    INCY
    Incyte
    10 15 0
    BPMC
    Blueprint Medicines
    9 5 1
  • Is INCY or BPMC More Risky?

    Incyte has a beta of 0.699, which suggesting that the stock is 30.125% less volatile than S&P 500. In comparison Blueprint Medicines has a beta of 0.616, suggesting its less volatile than the S&P 500 by 38.367%.

  • Which is a Better Dividend Stock INCY or BPMC?

    Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Blueprint Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Incyte pays -- of its earnings as a dividend. Blueprint Medicines pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios INCY or BPMC?

    Incyte quarterly revenues are $1.2B, which are larger than Blueprint Medicines quarterly revenues of $146.4M. Incyte's net income of $201.2M is higher than Blueprint Medicines's net income of -$50M. Notably, Incyte's price-to-earnings ratio is 267.15x while Blueprint Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 3.61x versus 11.50x for Blueprint Medicines. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INCY
    Incyte
    3.61x 267.15x $1.2B $201.2M
    BPMC
    Blueprint Medicines
    11.50x -- $146.4M -$50M
  • Which has Higher Returns INCY or EXEL?

    Exelixis has a net margin of 17.07% compared to Incyte's net margin of 24.68%. Incyte's return on equity of 0.81% beat Exelixis's return on equity of 23.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    INCY
    Incyte
    92.49% $1.02 $3.4B
    EXEL
    Exelixis
    96.48% $0.48 $2.2B
  • What do Analysts Say About INCY or EXEL?

    Incyte has a consensus price target of $78.26, signalling upside risk potential of 8.49%. On the other hand Exelixis has an analysts' consensus of $36.89 which suggests that it could grow by 0.1%. Given that Incyte has higher upside potential than Exelixis, analysts believe Incyte is more attractive than Exelixis.

    Company Buy Ratings Hold Ratings Sell Ratings
    INCY
    Incyte
    10 15 0
    EXEL
    Exelixis
    8 9 0
  • Is INCY or EXEL More Risky?

    Incyte has a beta of 0.699, which suggesting that the stock is 30.125% less volatile than S&P 500. In comparison Exelixis has a beta of 0.529, suggesting its less volatile than the S&P 500 by 47.112%.

  • Which is a Better Dividend Stock INCY or EXEL?

    Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exelixis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Incyte pays -- of its earnings as a dividend. Exelixis pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios INCY or EXEL?

    Incyte quarterly revenues are $1.2B, which are larger than Exelixis quarterly revenues of $566.8M. Incyte's net income of $201.2M is higher than Exelixis's net income of $139.9M. Notably, Incyte's price-to-earnings ratio is 267.15x while Exelixis's PE ratio is 20.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 3.61x versus 5.03x for Exelixis. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INCY
    Incyte
    3.61x 267.15x $1.2B $201.2M
    EXEL
    Exelixis
    5.03x 20.82x $566.8M $139.9M
  • Which has Higher Returns INCY or HALO?

    Halozyme Therapeutics has a net margin of 17.07% compared to Incyte's net margin of 45.98%. Incyte's return on equity of 0.81% beat Halozyme Therapeutics's return on equity of 162.37%.

    Company Gross Margin Earnings Per Share Invested Capital
    INCY
    Incyte
    92.49% $1.02 $3.4B
    HALO
    Halozyme Therapeutics
    85.89% $1.06 $1.9B
  • What do Analysts Say About INCY or HALO?

    Incyte has a consensus price target of $78.26, signalling upside risk potential of 8.49%. On the other hand Halozyme Therapeutics has an analysts' consensus of $66.11 which suggests that it could grow by 14.54%. Given that Halozyme Therapeutics has higher upside potential than Incyte, analysts believe Halozyme Therapeutics is more attractive than Incyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    INCY
    Incyte
    10 15 0
    HALO
    Halozyme Therapeutics
    3 4 0
  • Is INCY or HALO More Risky?

    Incyte has a beta of 0.699, which suggesting that the stock is 30.125% less volatile than S&P 500. In comparison Halozyme Therapeutics has a beta of 1.254, suggesting its more volatile than the S&P 500 by 25.393%.

  • Which is a Better Dividend Stock INCY or HALO?

    Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Halozyme Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Incyte pays -- of its earnings as a dividend. Halozyme Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios INCY or HALO?

    Incyte quarterly revenues are $1.2B, which are larger than Halozyme Therapeutics quarterly revenues of $298M. Incyte's net income of $201.2M is higher than Halozyme Therapeutics's net income of $137M. Notably, Incyte's price-to-earnings ratio is 267.15x while Halozyme Therapeutics's PE ratio is 16.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 3.61x versus 7.35x for Halozyme Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INCY
    Incyte
    3.61x 267.15x $1.2B $201.2M
    HALO
    Halozyme Therapeutics
    7.35x 16.83x $298M $137M
  • Which has Higher Returns INCY or SNDX?

    Syndax Pharmaceuticals has a net margin of 17.07% compared to Incyte's net margin of -673.01%. Incyte's return on equity of 0.81% beat Syndax Pharmaceuticals's return on equity of -67.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    INCY
    Incyte
    92.49% $1.02 $3.4B
    SNDX
    Syndax Pharmaceuticals
    -- -$0.98 $366.4M
  • What do Analysts Say About INCY or SNDX?

    Incyte has a consensus price target of $78.26, signalling upside risk potential of 8.49%. On the other hand Syndax Pharmaceuticals has an analysts' consensus of $36.23 which suggests that it could grow by 121.19%. Given that Syndax Pharmaceuticals has higher upside potential than Incyte, analysts believe Syndax Pharmaceuticals is more attractive than Incyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    INCY
    Incyte
    10 15 0
    SNDX
    Syndax Pharmaceuticals
    10 1 0
  • Is INCY or SNDX More Risky?

    Incyte has a beta of 0.699, which suggesting that the stock is 30.125% less volatile than S&P 500. In comparison Syndax Pharmaceuticals has a beta of 0.900, suggesting its less volatile than the S&P 500 by 10.021%.

  • Which is a Better Dividend Stock INCY or SNDX?

    Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Syndax Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Incyte pays -- of its earnings as a dividend. Syndax Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios INCY or SNDX?

    Incyte quarterly revenues are $1.2B, which are larger than Syndax Pharmaceuticals quarterly revenues of $12.5M. Incyte's net income of $201.2M is higher than Syndax Pharmaceuticals's net income of -$84.1M. Notably, Incyte's price-to-earnings ratio is 267.15x while Syndax Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 3.61x versus -- for Syndax Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INCY
    Incyte
    3.61x 267.15x $1.2B $201.2M
    SNDX
    Syndax Pharmaceuticals
    -- -- $12.5M -$84.1M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will AMD Beat the S&P 500?
Will AMD Beat the S&P 500?

High-performance and adaptive computing leader Advanced Micro Devices (NASDAQ:AMD) is…

Why Did Walmart Stock Fall?
Why Did Walmart Stock Fall?

Walmart (NYSE:WMT) tumbled in spite of strong Q4 results that…

Is Cadence Stock a Buy, Sell or Hold?
Is Cadence Stock a Buy, Sell or Hold?

Cadence Design Systems (NASDAQ:CDNS) has seen its stock move sharply…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Sell
48
Is MSFT Stock a Buy?

Market Cap: $3T
P/E Ratio: 35x

Alerts

Sell
2
GLOB alert for Feb 22

Globant SA [GLOB] is down 27.81% over the past day.

Sell
42
CELH alert for Feb 22

Celsius Holdings [CELH] is up 27.77% over the past day.

Buy
60
HIMS alert for Feb 22

Hims & Hers Health [HIMS] is down 25.64% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock